KR20230051199A - 세페타프로스트를 함유하는 의약 제제 - Google Patents

세페타프로스트를 함유하는 의약 제제 Download PDF

Info

Publication number
KR20230051199A
KR20230051199A KR1020237006743A KR20237006743A KR20230051199A KR 20230051199 A KR20230051199 A KR 20230051199A KR 1020237006743 A KR1020237006743 A KR 1020237006743A KR 20237006743 A KR20237006743 A KR 20237006743A KR 20230051199 A KR20230051199 A KR 20230051199A
Authority
KR
South Korea
Prior art keywords
glaucoma
ocular hypertension
treatment
cefetaprost
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237006743A
Other languages
English (en)
Korean (ko)
Inventor
야스코 야마모토
다카즈미 다니구치
아츠시 시마자키
에리카 기무라
Original Assignee
산텐 세이야꾸 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 산텐 세이야꾸 가부시키가이샤 filed Critical 산텐 세이야꾸 가부시키가이샤
Publication of KR20230051199A publication Critical patent/KR20230051199A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020237006743A 2020-08-13 2021-08-12 세페타프로스트를 함유하는 의약 제제 Pending KR20230051199A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020136796 2020-08-13
JPJP-P-2020-136796 2020-08-13
PCT/JP2021/029701 WO2022034909A1 (ja) 2020-08-13 2021-08-12 セペタプロストを含有する医薬製剤

Publications (1)

Publication Number Publication Date
KR20230051199A true KR20230051199A (ko) 2023-04-17

Family

ID=80248014

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237006743A Pending KR20230051199A (ko) 2020-08-13 2021-08-12 세페타프로스트를 함유하는 의약 제제

Country Status (7)

Country Link
US (1) US20230285411A1 (cg-RX-API-DMAC7.html)
EP (1) EP4197540A4 (cg-RX-API-DMAC7.html)
JP (1) JPWO2022034909A1 (cg-RX-API-DMAC7.html)
KR (1) KR20230051199A (cg-RX-API-DMAC7.html)
CN (1) CN115768433A (cg-RX-API-DMAC7.html)
TW (1) TW202220666A (cg-RX-API-DMAC7.html)
WO (1) WO2022034909A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202404569A (zh) 2022-04-22 2024-02-01 日商參天製藥股份有限公司 含有賽佩普斯特(Sepetaprost)之眼科用組合物
TW202517277A (zh) * 2023-10-10 2025-05-01 日商參天製藥股份有限公司 含有賽佩普斯特(Sepetaprost)之點眼液

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011013651A (ja) 2009-07-03 2011-01-20 Mitsumasa Maeda フレキシブルディスプレイのれん

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101768235B1 (ko) 2009-07-28 2017-08-14 오노 야꾸힝 고교 가부시키가이샤 이환식 화합물 및 이의 의약 용도
WO2019124489A1 (ja) * 2017-12-21 2019-06-27 参天製薬株式会社 セペタプロストとep2アゴニストとの組み合わせ医薬
EP3730138B1 (en) * 2017-12-21 2024-02-14 Santen Pharmaceutical Co., Ltd. Combination of sepetaprost and ripasudil for use in the prophylaxis or treatment of glaucoma or ocular hypertension
US11666563B2 (en) * 2017-12-28 2023-06-06 Santen Pharmaceutical Co., Ltd. Pharmaceutical preparation containing pyridyl aminoacetic acid compound
JP2022508715A (ja) * 2018-10-15 2022-01-19 オキュフィア・ファーマ・インコーポレイテッド 緑内障および関連状態の処置のための方法および組成物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011013651A (ja) 2009-07-03 2011-01-20 Mitsumasa Maeda フレキシブルディスプレイのれん

Also Published As

Publication number Publication date
JPWO2022034909A1 (cg-RX-API-DMAC7.html) 2022-02-17
EP4197540A4 (en) 2024-06-19
TW202220666A (zh) 2022-06-01
US20230285411A1 (en) 2023-09-14
WO2022034909A1 (ja) 2022-02-17
CN115768433A (zh) 2023-03-07
EP4197540A1 (en) 2023-06-21

Similar Documents

Publication Publication Date Title
JP4934653B2 (ja) Rhoキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤
JP5174777B2 (ja) Rhoキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤
JP2024160001A (ja) 緑内障予防又は治療のための薬物療法
JP4482726B2 (ja) Rhoキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤
EP1526895A2 (en) Methods for treating carbonic anhydrase mediated disorders
ES2972934T3 (es) Combinación de sepetaprost y ripasudil para su uso en la profilaxis o tratamiento del glaucoma o hipertensión ocular
EP4197540A1 (en) Drug formulation containing sepetaprost
KR20200103719A (ko) 피리딜아미노아세트산 화합물을 함유하는 의약 제제
JP2012250951A (ja) アデノシン誘導体とプロスタグランジン類とβ受容体遮断薬の組合せ剤
JP2012250949A (ja) アデノシン誘導体と炭酸脱水酵素阻害剤とβ受容体遮断薬の組合せ剤
JP2012250947A (ja) アデノシン誘導体とβ受容体遮断薬の組合せ剤
EA043474B1 (ru) Комбинация омиденепага
JP2012250952A (ja) アデノシン誘導体とRhoキナーゼ阻害剤の組合せ剤
JP2012250948A (ja) アデノシン誘導体と炭酸脱水酵素阻害剤の組合せ剤

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902